Clarivate to Sell Life Sciences Unit to Altaris for $600M, Refocus Core Business
Clarivate NYSE: CLVT said it has reached an agreement to sell substantially all of its Life Sciences & Healthcare segment to Altaris, an investment firm focused on the healthcare industry, in a transaction valued at $600 million.
Clarivate: Business Showed Signs Of Stabilization, But It Is Not Enough
Clarivate delivered improved Q1 2026 results, with organic growth turning positive at 0.6% and margin expansion, but reported revenue still declined year over year. Segment trends stabilized, notably with Academia & Government and Life Sciences & Healthcare returning to growth, though IPPG remained a drag at -1.3% organic growth. AI-driven product enhancements and the Value Creation Plan could accelerate organic growth, but sustained improvement is needed before a re-rating is justified.
Clarivate Plc (CLVT) Q1 2026 Earnings Call Transcript
Clarivate Plc (CLVT) Q1 2026 Earnings Call Transcript
Compared to Estimates, Clarivate (CLVT) Q1 Earnings: A Look at Key Metrics
Although the revenue and EPS for Clarivate (CLVT) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Clarivate PLC (CLVT) Tops Q1 Earnings and Revenue Estimates
Clarivate PLC (CLVT) came out with quarterly earnings of $0.18 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.14 per share a year ago.
Clarivate: The Data Intelligence Company Flying Under the Radar
Most investors have never heard of Clarivate. The company operates largely outside mainstream investor attention.
Clarivate Plc (CLVT) Presents at Wolfe Research FinTech Forum Transcript
Clarivate Plc (CLVT) Presents at Wolfe Research FinTech Forum Transcript
Clarivate: Deleveraging And FCF Growth Support A Re-Rating
Clarivate is executing a turnaround, with management focusing on debt reduction, divestitures, and share buybacks after years of value-destructive acquisitions. Q4 and FY25 results marked the first time CLVT met initial full-year guidance since 2019, with sequential organic ACV growth and 88% recurring revenue. 2026 guidance projects organic ACV growth of 2–3%, adjusted EBITDA margin near 43%, and FCF around $400M, despite headline revenue decline from low-margin business exits.
Clarivate: A Tough Operating Backdrop Ahead
Clarivate (CLVT) remains a hold as core organic growth continues to deteriorate, with no evidence of recovery despite multiple compression. AI-driven shifts in user behavior and low barriers to entry are intensifying competitive threats, raising doubts about CLVT's long-term growth prospects. Strategic positives include the planned sale of the underperforming LSH segment and improved recurring revenue mix, but these do not offset weak fundamentals.
Surging Earnings Estimates Signal Upside for Clarivate (CLVT) Stock
Clarivate PLC (CLVT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Clarivate Plc (CLVT) Q4 2025 Earnings Call Transcript
Clarivate Plc (CLVT) Q4 2025 Earnings Call Transcript
Compared to Estimates, Clarivate (CLVT) Q4 Earnings: A Look at Key Metrics
Although the revenue and EPS for Clarivate (CLVT) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
